Developer docs
API playgroundTry for free, no card

Search company profiles

HAL Allergy Group

Full company profile

uuid000glp2

Namestring
HAL Allergy Group
Legal namestring
HAL Allergy Holding B.V.
Websiteurl
hal-allergy.com
Company typeenum
Private
Founded yearint
1959
Descriptiontext

HAL Allergy Group is a privately held Dutch biopharmaceutical company headquartered at the Bio Science Park in Leiden, Netherlands, with 251-500 employees. Founded in 1959 and wholly owned by family-owned Droege Group AG, the company develops, manufactures, and distributes allergen immunotherapies (AIT) for the treatment and prevention of allergic diseases. Itself describes as one of the European top players in allergy immunotherapy, HAL Allergy markets products in 16 countries through direct sales organizations in Germany, Poland, Austria, Italy, and Spain, supplemented by distribution partners elsewhere.

The company's core product portfolio consists of subcutaneous immunotherapy (SCIT) injections and sublingual immunotherapy (SLIT) drops, including the SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml products, alongside allergen diagnostic products for in-vivo diagnosis. The proprietary technology platform centers on modified allergen extracts produced at a GMP-certified facility. The development pipeline includes PM50k (house dust mite SCIT, Phase III completed June 2026 with a 30% reduction in Total Combined Rhinitis Scores versus placebo), peanut and tree nut (cashew, hazelnut, walnut) food allergy immunotherapies, and a ragweed respiratory allergy candidate. HAL Allergy also operates HALIX B.V., a wholly-owned CDMO spun off in 2021 that provides GMP biologics manufacturing for external clients.

Revenue is generated through pharmaceutical product sales of SCIT, SLIT, and diagnostic products, distributed via a field sales force targeting allergists, ENT specialists, dermatologists, pulmonologists, and pediatricians. A March 2026 distribution partnership with Advanz Pharma adds biosimilar commercialization in dermatology, pulmonology, and allergology across Germany and Austria. The company targets two primary persona segments: healthcare professionals who prescribe AIT, and allergy patients seeking disease-modifying rather than symptomatic therapy. HAL Allergy holds first-mover regulatory positioning as the first company to achieve marketing authorizations under Germany's Therapieallergene-Verordnung (TAV).

Short descriptiontext

HAL Allergy Group is a privately held Dutch biopharmaceutical company founded in 1959 that develops, manufactures, and distributes subcutaneous and sublingual allergen immunotherapies for allergic rhinitis, asthma, venom, and food allergies, marketing products in 16 European countries and serving healthcare professionals and allergy patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allergen immunotherapy, sublingual immunotherapy drops, subcutaneous immunotherapy products, allergy diagnostic products, biopharmaceutical manufacturing
Industry1 code
PRIMARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Allergy Immunotherapy Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

HAL Allergy generates revenue through the sale of allergy immunotherapy products (SCIT and SLIT) and diagnostic products for allergic diseases. Products are marketed in 16 countries through direct sales organizations and distribution partners.

hal-allergy.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1myAllergy
Description

Patient information portal (www.allergy.de) helping patients understand and manage allergies in collaboration with allergists.

hal-allergy.com
Core offering1 text field

HAL Allergy Group develops, produces, and distributes allergen immunotherapies for the treatment and prevention of allergic diseases. Its portfolio includes subcutaneous immunotherapy (SCIT) injections, sublingual immunotherapy (SLIT) drops such as SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, and allergen diagnostic products. Products are manufactured at a GMP-certified facility in Leiden, Netherlands and marketed in 16 European countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • SUBLIVAC Birch 40,000 AUN/ml demonstrated 32% improvement in combined symptom and medication score compared to placebo in Phase III trials
+1 more record
Product overview1 text field

HAL Allergy Group is a European biopharmaceutical company and one of the top players in allergy immunotherapy, offering a portfolio of allergen immunotherapies for treatment and prevention of allergic diseases. The core product portfolio comprises Subcutaneous Immunotherapy (SCIT) injections and Sublingual Immunotherapy (SLIT) drops including branded products SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, alongside Diagnostic products for allergy diagnosis. The company operates a GMP-certified manufacturing facility in Leiden, Netherlands and markets products in 16 countries across Europe. The pipeline includes PM50k for house dust mite allergy (Phase III), peanut and tree nut immunotherapy candidates, and ragweed allergy treatments. Supporting services include the myAllergy patient information portal.

Product and service5 records
1Subcutaneous Immunotherapy (SCIT)
CategoryAllergen Immunotherapy
Description

Injection-based allergen immunotherapy treatment administered under the skin for respiratory allergies, venom allergies (wasp and bee stings), and food allergies. Prescribed by allergists, ENT specialists, dermatologists, pulmonologists, and pediatricians.

2Sublingual Immunotherapy (SLIT)
CategoryAllergen Immunotherapy
Description

Drops or liquid preparations containing allergen extracts in glycerinated phosphate buffer, administered under the tongue for treatment of allergic rhinitis, rhino-conjunctivitis, and other allergic diseases. Prescribed for adult patients.

3SUBLIVAC Birch 40,000 AUN/ml
CategoryAllergen Immunotherapy
Description

Sublingual immunotherapy drops for treatment of allergic rhinitis and rhino-conjunctivitis in adults caused by birch pollen sensitisation; liquid preparation for sublingual administration containing allergen extracts in glycerinated phosphate buffer.

4SUBLIVAC Trees 40,000 AUN/ml
CategoryAllergen Immunotherapy
Description

Sublingual immunotherapy drops for treatment of allergic rhinitis and rhino-conjunctivitis in adults caused by tree pollen sensitisation; liquid preparation for sublingual administration containing allergen extracts in glycerinated phosphate buffer.

5Diagnostic Products
CategoryAllergy Diagnostics
Description

Allergen diagnostic products for in-vivo allergy diagnosis, supporting the identification of allergic sensitisation in patients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-19
Description

Multi-year strategic distribution partnership in dermatology, pulmonology and allergology. The partnership combines HAL Allergy's expertise in the allergy sector and strong presence with specialists with Advanz Pharma's international experience in marketing specialized medicines and growing role in the biosimilar segment. Goal is to expand access to modern biosimilar therapies for patients in Germany and Austria.

2HOFFRICHTER GmbH
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-03-31
Description

Both companies are part of Droege Group and jointly donated respiratory ventilators worth €350,000 to Ukraine through the #WirtschaftHilft initiative.

hal-allergy.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-03-26
Description

Partnership to provide telephone counseling ('Prima Linea' initiative) for doctors and medical personnel in regions most affected by coronavirus in Italy during the COVID-19 pandemic.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HALIX is a corporate venture and spin-off of HAL Allergy, serving as a Contract Development and Manufacturing Organization (CDMO) for GMP manufacturing of biologics. HAL Allergy and HALIX work together, with HALIX providing contract manufacturing services for biopharmaceutical products.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Danish-listed global leader in allergy immunotherapy (SCIT, SLIT tablets, diagnostics). Directly competes with HAL Allergy across the same allergen categories, prescriber base, and European geographies, but with materially larger scale and US/Asia presence.

TypeDirect peer
Description

France-based allergen immunotherapy specialist offering SCIT, SLIT, and diagnostics. Direct competitor to HAL Allergy in European allergy immunotherapy with overlapping product formats and physician targets.

TypeDirect peer
Description

UK-listed specialty vaccine company developing allergy immunotherapies (Pollinex, VLP-based candidates). Competes with HAL Allergy in subcutaneous and sublingual immunotherapy across European markets and shares a similar mid-cap, R&D-intensive profile.

TypeDirect peer
Description

Spanish allergen immunotherapy manufacturer producing SCIT and SLIT products and diagnostics. Direct competitor to HAL Allergy, particularly strong in Spain and Latin America, with comparable product formats and allergy-clinic focus.

TypeDirect peer
Description

French-listed biotech developing Viaskin epicutaneous patches for food allergy (peanut, milk). Competes with HAL Allergy in the food allergy immunotherapy space and shares the same regulatory and reimbursement challenges.

TypeDirect peer
Description

US-based food allergy immunotherapy developer (Palforzia peanut OIT), now part of Nestlé Health Science. Direct competitor in peanut allergy immunotherapy where HAL Allergy's pipeline is also advancing.

TypeDirect peer
Description

German allergen immunotherapy specialist producing SCIT and SLIT products. Regional direct competitor to HAL Allergy in the German market where HAL Allergy has its TAV-authorized portfolio.

TypeEmerging player
Description

Austrian biotech developing recombinant allergen-based immunotherapies, including for grass and birch pollen. Comparable technology platform and allergen focus to HAL Allergy but at earlier development stage.

9Anergis
TypeEmerging player
Description

Swiss clinical-stage company developing contiguous overlapping peptide-based allergy vaccines (e.g., birch pollen). Adjacent allergen immunotherapy competitor with overlapping birch pollen target to HAL Allergy's SUBLIVAC Birch.

TypeBroad incumbent
Description

Global pharmaceutical major whose Dupixent (dupilumab) biologic is increasingly used for severe asthma and chronic rhinosinusitis with nasal polyps. Competes indirectly with HAL Allergy's respiratory immunotherapy portfolio by treating overlapping patient populations with a different mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HAL Allergy Group

Allergy Immunotherapy Pharmaceuticalshal-allergy.com

HAL Allergy Group is a privately held Dutch biopharmaceutical company founded in 1959 that develops, manufactures, and distributes subcutaneous and sublingual allergen immunotherapies for allergic rhinitis, asthma, venom, and food allergies, marketing products in 16 European countries and serving healthcare professionals and allergy patients.

What HAL Allergy Group does

HAL Allergy Group is a privately held Dutch biopharmaceutical company headquartered at the Bio Science Park in Leiden, Netherlands, with 251-500 employees. Founded in 1959 and wholly owned by family-owned Droege Group AG, the company develops, manufactures, and distributes allergen immunotherapies (AIT) for the treatment and prevention of allergic diseases. Itself describes as one of the European top players in allergy immunotherapy, HAL Allergy markets products in 16 countries through direct sales organizations in Germany, Poland, Austria, Italy, and Spain, supplemented by distribution partners elsewhere.

The company's core product portfolio consists of subcutaneous immunotherapy (SCIT) injections and sublingual immunotherapy (SLIT) drops, including the SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml products, alongside allergen diagnostic products for in-vivo diagnosis. The proprietary technology platform centers on modified allergen extracts produced at a GMP-certified facility. The development pipeline includes PM50k (house dust mite SCIT, Phase III completed June 2026 with a 30% reduction in Total Combined Rhinitis Scores versus placebo), peanut and tree nut (cashew, hazelnut, walnut) food allergy immunotherapies, and a ragweed respiratory allergy candidate. HAL Allergy also operates HALIX B.V., a wholly-owned CDMO spun off in 2021 that provides GMP biologics manufacturing for external clients.

Revenue is generated through pharmaceutical product sales of SCIT, SLIT, and diagnostic products, distributed via a field sales force targeting allergists, ENT specialists, dermatologists, pulmonologists, and pediatricians. A March 2026 distribution partnership with Advanz Pharma adds biosimilar commercialization in dermatology, pulmonology, and allergology across Germany and Austria. The company targets two primary persona segments: healthcare professionals who prescribe AIT, and allergy patients seeking disease-modifying rather than symptomatic therapy. HAL Allergy holds first-mover regulatory positioning as the first company to achieve marketing authorizations under Germany's Therapieallergene-Verordnung (TAV).

HAL Allergy Group firmographics

Firmographics
Name
HAL Allergy Group
Legal name
HAL Allergy Holding B.V.
Website
https://hal-allergy.com
Company type
Private
Founded year
1959
Operating status
Operating
Headcount range
251–500 employees
Short description
HAL Allergy Group is a privately held Dutch biopharmaceutical company founded in 1959 that develops, manufactures, and distributes subcutaneous and sublingual allergen immunotherapies for allergic rhinitis, asthma, venom, and food allergies, marketing products in 16 European countries and serving healthcare professionals and allergy patients.
Ownership category
akta.pro rank

HAL Allergy Group industry classification

Industry
Product category
Allergy Immunotherapy Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Allergen immunotherapy
  • Sublingual immunotherapy drops
  • Subcutaneous immunotherapy products
  • Allergy diagnostic products
  • Biopharmaceutical manufacturing

Where HAL Allergy Group is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices4 records

Markets served

HAL Allergy Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: HAL Allergy generates revenue through the sale of allergy immunotherapy products (SCIT and SLIT) and diagnostic products for allergic diseases. Products are marketed in 16 countries through direct sales organizations and distribution partners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

HAL Allergy Group product offering

Product offering

Core offering

HAL Allergy Group develops, produces, and distributes allergen immunotherapies for the treatment and prevention of allergic diseases. Its portfolio includes subcutaneous immunotherapy (SCIT) injections, sublingual immunotherapy (SLIT) drops such as SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, and allergen diagnostic products. Products are manufactured at a GMP-certified facility in Leiden, Netherlands and marketed in 16 European countries.

Product overview

HAL Allergy Group is a European biopharmaceutical company and one of the top players in allergy immunotherapy, offering a portfolio of allergen immunotherapies for treatment and prevention of allergic diseases. The core product portfolio comprises Subcutaneous Immunotherapy (SCIT) injections and Sublingual Immunotherapy (SLIT) drops including branded products SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, alongside Diagnostic products for allergy diagnosis. The company operates a GMP-certified manufacturing facility in Leiden, Netherlands and markets products in 16 countries across Europe. The pipeline includes PM50k for house dust mite allergy (Phase III), peanut and tree nut immunotherapy candidates, and ragweed allergy treatments. Supporting services include the myAllergy patient information portal.

Differentiator

Problem solved

Functional benefit

Brands

  • myAllergy: Patient information portal (www.allergy.de) helping patients understand and manage allergies in collaboration with allergists.

Products and services

  • Subcutaneous Immunotherapy (SCIT) Injection-based allergen immunotherapy treatment administered under the skin for respiratory allergies, venom allergies (wasp and bee stings), and food allergies. Prescribed by allergists, ENT specialists, dermatologists, pulmonologists, and pediatricians.
  • Sublingual Immunotherapy (SLIT) Drops or liquid preparations containing allergen extracts in glycerinated phosphate buffer, administered under the tongue for treatment of allergic rhinitis, rhino-conjunctivitis, and other allergic diseases. Prescribed for adult patients.
  • SUBLIVAC Birch 40,000 AUN/ml Sublingual immunotherapy drops for treatment of allergic rhinitis and rhino-conjunctivitis in adults caused by birch pollen sensitisation; liquid preparation for sublingual administration containing allergen extracts in glycerinated phosphate buffer.
  • SUBLIVAC Trees 40,000 AUN/ml Sublingual immunotherapy drops for treatment of allergic rhinitis and rhino-conjunctivitis in adults caused by tree pollen sensitisation; liquid preparation for sublingual administration containing allergen extracts in glycerinated phosphate buffer.
  • Diagnostic Products Allergen diagnostic products for in-vivo allergy diagnosis, supporting the identification of allergic sensitisation in patients.

Quantifiable outcome

  • SUBLIVAC Birch 40,000 AUN/ml demonstrated 32% improvement in combined symptom and medication score compared to placebo in Phase III trials
  • +1 more outcomes

Companies that use HAL Allergy Group

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

HAL Allergy Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

HAL Allergy Group partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Advanz PharmacoreChannel Partner/ Reseller/ Distributor · 19 March 2026Multi-year strategic distribution partnership in dermatology, pulmonology and allergology. The partnership combines HAL Allergy's expertise in the allergy sector and strong presence with specialists with Advanz Pharma's international experience in marketing specialized medicines and growing role in the biosimilar segment. Goal is to expand access to modern biosimilar therapies for patients in Germany and Austria.
  • HOFFRICHTER GmbHminorStrategic or Co-development Partner · 31 March 2022Both companies are part of Droege Group and jointly donated respiratory ventilators worth €350,000 to Ukraine through the #WirtschaftHilft initiative.
  • Avalon CounselingminorStrategic or Co-development Partner · 26 March 2020Partnership to provide telephone counseling ('Prima Linea' initiative) for doctors and medical personnel in regions most affected by coronavirus in Italy during the COVID-19 pandemic.
  • HALIX B.V.coreStrategic or Co-development PartnerHALIX is a corporate venture and spin-off of HAL Allergy, serving as a Contract Development and Manufacturing Organization (CDMO) for GMP manufacturing of biologics. HAL Allergy and HALIX work together, with HALIX providing contract manufacturing services for biopharmaceutical products.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

HAL Allergy Group competitors and assessment

Company assessment

Direct peers

  • ALK-Abelló: Danish-listed global leader in allergy immunotherapy (SCIT, SLIT tablets, diagnostics). Directly competes with HAL Allergy across the same allergen categories, prescriber base, and European geographies, but with materially larger scale and US/Asia presence.
  • Stallergenes Greer: France-based allergen immunotherapy specialist offering SCIT, SLIT, and diagnostics. Direct competitor to HAL Allergy in European allergy immunotherapy with overlapping product formats and physician targets.
  • Allergy Therapeutics: UK-listed specialty vaccine company developing allergy immunotherapies (Pollinex, VLP-based candidates). Competes with HAL Allergy in subcutaneous and sublingual immunotherapy across European markets and shares a similar mid-cap, R&D-intensive profile.
  • Leti Pharma: Spanish allergen immunotherapy manufacturer producing SCIT and SLIT products and diagnostics. Direct competitor to HAL Allergy, particularly strong in Spain and Latin America, with comparable product formats and allergy-clinic focus.
  • DBV Technologies: French-listed biotech developing Viaskin epicutaneous patches for food allergy (peanut, milk). Competes with HAL Allergy in the food allergy immunotherapy space and shares the same regulatory and reimbursement challenges.
  • Aimmune Therapeutics: US-based food allergy immunotherapy developer (Palforzia peanut OIT), now part of Nestlé Health Science. Direct competitor in peanut allergy immunotherapy where HAL Allergy's pipeline is also advancing.
  • ROXALL Medizin: German allergen immunotherapy specialist producing SCIT and SLIT products. Regional direct competitor to HAL Allergy in the German market where HAL Allergy has its TAV-authorized portfolio.

Emerging players

  • Biomay: Austrian biotech developing recombinant allergen-based immunotherapies, including for grass and birch pollen. Comparable technology platform and allergen focus to HAL Allergy but at earlier development stage.
  • Anergis: Swiss clinical-stage company developing contiguous overlapping peptide-based allergy vaccines (e.g., birch pollen). Adjacent allergen immunotherapy competitor with overlapping birch pollen target to HAL Allergy's SUBLIVAC Birch.

Broad incumbents

  • Sanofi (Dupixent franchise): Global pharmaceutical major whose Dupixent (dupilumab) biologic is increasingly used for severe asthma and chronic rhinosinusitis with nasal polyps. Competes indirectly with HAL Allergy's respiratory immunotherapy portfolio by treating overlapping patient populations with a different mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

HAL Allergy Group social profiles

Digital presence

HAL Allergy Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HAL Allergy Group leadership team

Management profile

Number of profiles

Profiles11 records

HAL Allergy Group subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

HAL Allergy Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HAL Allergy Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAL Allergy Group

What does HAL Allergy Group do?

HAL Allergy Group develops, produces, and distributes allergen immunotherapies for the treatment and prevention of allergic diseases. Its portfolio includes subcutaneous immunotherapy (SCIT) injections, sublingual immunotherapy (SLIT) drops such as SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, and allergen diagnostic products. Products are manufactured at a GMP-certified facility in Leiden, Netherlands and marketed in 16 European countries.

Is HAL Allergy Group a public or private company?

HAL Allergy Group is a private company. It is classified as corporate owned and is currently operating.

When was HAL Allergy Group founded?

HAL Allergy Group was founded in 1959. It employs 251 to 500 people.

Where is HAL Allergy Group based?

HAL Allergy Group is headquartered in Leiden, Netherlands, in the Europe region.

How does HAL Allergy Group make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are HAL Allergy Group's main competitors?

Direct peers on record are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, Leti Pharma, DBV Technologies, Aimmune Therapeutics and ROXALL Medizin. Emerging players are Biomay and Anergis. Sanofi (Dupixent franchise) is listed as a broad incumbent.

Does HAL Allergy Group have an API?

No public API is recorded for HAL Allergy Group.

What industry is HAL Allergy Group in?

HAL Allergy Group's product category is Allergy Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEurope And Japan Allergy Immunotherapy Market Size Forecasts 2026-2033: Analyzing Industry Growth and Trends |ALK-Abell, Stallergenes Greer, HAL Allergy Group, Allergy TherapeuticsThe article reports on the forecast of the Europe and Japan allergy immunotherapy market from 2026 to 2033, emphasizing industry growth, regional shifts, and key players. It highlights market segmentation by treatment type, allergy type, and distribution channels, as well as coverage of regional markets and major companies involved.GlobeNewswireGlobal Allergy Immunotherapy Market Poised to Reach USD 4,161.9 Million by 2035, Driven by 7.9% CAGR and Innovation in SLIT | Future Market Insights, Inc.The global allergy immunotherapy market is projected to grow from $1.942 billion in 2025 to $4.162 billion by 2035, a CAGR of 7.9%. Growth is driven by rising allergy prevalence, personalized medicine demand, and sublingual immunotherapy (SLIT) adoption. North America leads, with Asia-Pacific expected to see the highest growth.PR NewswireInsights on the Allergy Immunotherapies Global Market to 2027 - by Treatment Type, Allergy Type, Distribution Channel and RegionResearchAndMarkets published a global market report estimating the allergy immunotherapies market reached US$ 2.56 billion in 2021 and is projected to grow to US$ 4.63 billion by 2027, at a compound annual growth rate of 10.2% during 2022-2027. Market growth is driven by rising allergy prevalence globally, increasing healthcare expenditure, growing awareness of immunotherapy treatments, and advancements in drug development technologies and allergy diagnostics. The report analyzes the competitive landscape including ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck Group, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG.PR NewswireInsights on the Allergy Immunotherapies Global Market to 2026 - by Treatment Type, Allergy Type, Distribution Channel and RegionResearch and Markets announced the addition of a global allergy immunotherapies market report to its offerings, projecting the market to grow from US$ 2.3 billion in 2020 to US$ 4.10 billion by 2026, representing a compound annual growth rate of 10.50%. The report attributes growth drivers to rising allergy prevalence, increasing healthcare expenditure, and advancements in immunotherapy drug development and diagnostics. Key companies analyzed in the competitive landscape include ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck Group, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG.PR NewswireAllergy Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025Reportlinker published a market research report on the global allergy immunotherapy market covering the forecast period from 2017 to 2025, analyzing market segments by treatment type (SCIT and SLIT), allergy type, distribution channel, and region. The report identifies major industry players including Stallergenes Greer, Aimmune Therapeutics, ALK-Abello A/S, Allergy Therapeutics, Merck KGaA (Allergopharma), HAL Allergy Group, DBV Technologies, Circassia, Biomay AG, and Anergis. The market has been geographically segmented across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.PR NewswirePeanut Allergy Pipeline Review and Therapeutics Development Market Research Report for H2 2015ReportsnReports.com has added the "Peanut Allergy - Pipeline Review, H2 2015" market research report to its catalog. The 67-page study provides a comprehensive overview of the therapeutic pipeline for peanut allergies, including analysis of drug targets and mechanisms of action. It features data on key players such as DBV Technologies S.A., HAL Allergy BV, and Immunomic Therapeutics, Inc.